A Hybrid Trial Approach by Combining 13C8-Lableded & Radiolabeled Brilaroxazine to Assess Absolute Bioavailability & hAME in a Single Clinical Trial

Brilaroxazine (BXZ, RP5063) is an investigational drug in development by Reviva Pharmaceuticals for neuropsychiatric & inflammatory disorders. It is a serotonin-dopamine modulator displaying partial agonist activity at D2/3/4 & 5-HT1A/2A receptors & antagonist activity at 5 HT2B/7 receptors with binding affinity for 5-HT2B > D2.

"*" indicates required fields

Company

This field is for validation purposes and should be left unchanged.

First Name*

Last Name*

Company*

State*